Chemo drugs approved in the past 144 months increased lifespan by an average of 2.1 months
How Much Do New Chemotherapy Drugs Extend Life? - Sept 2026
- Example: "The placebo group only lived 5.91 months, whereas the added drug group survived all the way to… 6.24 months "
- "So, they only lived a third of a month longer? That’s just 10 days. All the side effects and expense for an average of just 10 days? That’s why doctors shouldn’t use statistical jargon—like “significant improvement in survival”—while telling patients about the benefits of a new treatment. When patients hear the word “survival,” they’re not thinking about a week and a half."
- "Chemo is the primary treatment, but it is not curative; it’s just eking out a few extra weeks or months."
- [E]ven when postmarket studies show the new drugs to have no clinically meaningful benefit compared with [a sugar pill] placebo or observation, most drugs retain FDA [U.S. Food and Drug Administration] approval and remain on the market at prices comparable to those of the most expensive cancer drugs,” the same ridiculous prices.
Only new chemo drug approved by the FDA in the past decade extended life by even 3 years.
Claude AI
Classic cytotoxic chemotherapy: No cytotoxic drug approved since late 2016 comes close. The best I know of is oral azacitidine (Onureg, 2020) as maintenance therapy for AML. Median overall survival was 24.7 months vs 14.8 months with placebo, a gain of about 9.9 months [ONN QUAZAR]. That is well above typical. An analysis of FDA cancer drug approvals from 2003 to 2021 found a median overall survival gain of 2.80 months [JCO 2022].
Broader cancer drugs: The one approval that clears 36 months is midostaurin (2017), added to standard chemo for FLT3-mutated AML. Median survival was 74.7 months vs 25.6 months with placebo. However, the NEJM authors noted that the median gap may be large because of inflection points on the survival curves. They said the hazard ratio of 0.78 better reflects the benefit. Four-year survival was 51.4% vs 44.3%. [NEJM RATIFY]. So in practice, about 7 more patients per 100 were alive at 4 years. Nobody gained an average of 4 years.
Two other results are worth knowing:
- Nivolumab + ipilimumab for melanoma. This is the most famous large gap. Median survival was 71.9 months with the combination vs 19.9 months with ipilimumab alone [Targeted Onc]. It was first approved in 2015–early 2016, just outside your ten-year window, and the comparison was against another active drug.
- Olaparib for BRCA ovarian cancer (2018). This one might eventually qualify, but we don't know yet. Median survival was not reached with olaparib vs 75.2 months with placebo. The result did not meet the trial's pre-set significance threshold. At 7 years, 67.0% vs 46.5% were alive. [ASCO Post SOLO1]
Lorlatinib for ALK-positive lung cancer could also qualify someday, but its overall survival follow-up is still ongoing [ESMO CROWN].
Largest median survival gains, approvals since late 2016:
| Drug (FDA year) | Setting | Median OS, drug vs control | Gain | Ref |
|---|---|---|---|---|
| Midostaurin + chemo (2017) | FLT3+ AML | 74.7 vs 25.6 mo | ~49 mo (HR 0.78) | [NEJM] |
| Olaparib (2018) | BRCA+ ovarian, 1st line | Not reached vs 75.2 mo | Unknown; 7-yr OS 67% vs 46.5% | [ASCO Post] |
| Daratumumab + VMP (2018) | Myeloma, no transplant | 83.0 vs 53.6 mo | ~29 mo | [Leukemia 2026] |
| Alectinib (2017) | ALK+ lung, vs crizotinib | 81.1 vs 54.2 mo | ~27 mo (not significant) | [CancerNetwork] |
| Daratumumab + Rd (2019) | Myeloma, no transplant | 90.3 vs 64.1 mo | ~26 mo | [PubMed] |
| Nivolumab + ipilimumab (2018) | Kidney, int/poor risk | 46.7 vs 26.0 mo | ~21 mo | [ONN] |
| Oral azacitidine (2020) | AML maintenance (cytotoxic) | 24.7 vs 14.8 mo | ~10 mo | [ASCO Post] |
About the "lifespan" wording: trials report the difference in median overall survival, not lifespan added per person. When a survival curve flattens out near 50%, the median can jump by years even though only a few more patients survive, as in the midostaurin result. The hazard ratio and survival at fixed times, such as 5-year survival, are more reliable measures. By those measures, the gains above are real but modest. In several cases the benefit is concentrated in a subset of patients who become long-term survivors.